• head_banner_01

Europe style for Pharmaceutical Ingredients - Semaglutide for Type 2 Diabetes – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We have our own product sales staff, style crew, technical group, QC staff and package staff. We now have strict high quality management procedures for each approach. Also, all of our workers are experienced in printing subject for Tiotropium Bromide, Cardarine, 3 3-Dimethylbutyraldehyde, we could solve our customer problems asap and do the profit for our customer. If you need good service and quality , pls choose us , thanks !
Europe style for Pharmaceutical Ingredients - Semaglutide for Type 2 Diabetes – Gentolex Detail:

Product Detail

Name  Semaglutide
CAS number  910463-68-2
Molecular formula  C187H291N45O59
Molecular weight  4113.57754
EINECS Number  203-405-2

Synonyms

Sermaglutide; Semaglutide fandachem; Semaglutide impurity; Sermaglutide USP/EP; semaglutide; Sermaglutide CAS 910463 68 2; Ozempic, 

Description

Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogs, and semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has a better effect in the treatment of type 2 diabetes. Novo Nordisk has completed 6 Phase IIIa studies of semaglutide injection, and submitted a new drug registration application for semaglutide weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. A Marketing Authorization Application (MAA) was also submitted to the European Medicines Agency (EMA).

Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Application

Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes.

Bioactivity

Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analog, an agonist of GLP-1receptor, with a potential type 2 Therapeutic efficacy of diabetes mellitus (T2DM).

Quality System

In general, quality system and assurance is in place covering all stage of production of the finished product. Adequate manufacturing and control operations are performed in compliance with the approved procedures/ specifications. Change control and Deviation handling system is in place, and necessary impact assessment and investigation were conducted. Proper procedures are in place to ensure quality of product prior to release into the market.


Product detail pictures:

Europe style for Pharmaceutical Ingredients - Semaglutide for Type 2 Diabetes – Gentolex detail pictures

Europe style for Pharmaceutical Ingredients - Semaglutide for Type 2 Diabetes – Gentolex detail pictures


Related Product Guide:

Our well-equipped facilities and exceptional good quality manage throughout all stages of production enables us to guarantee total shopper satisfaction for Europe style for Pharmaceutical Ingredients - Semaglutide for Type 2 Diabetes – Gentolex , The product will supply to all over the world, such as: Johor, Singapore, Los Angeles, The best and original quality for spare parts is a most important factor for transportation. We may stick on supplying original and good quality parts even a little profit earned. God will bless us to do kindness business forever.
  • Sales manager is very enthusiastic and professional, gave us a great concessions and product quality is very good,thank you very much!
    5 Stars By Gail from Lesotho - 2017.05.31 13:26
    Wide range, good quality, reasonable prices and good service, advanced equipment, excellent talents and continuously strengthened technology forces,a nice business partner.
    5 Stars By Stephen from Mongolia - 2017.08.18 18:38
    Write your message here and send it to us